Skip to main content

Table 2 Laboratory, radiology findings and treatment of four passages patients

From: Epidemiological and clinical based study on four passages of COVID-19 patients: intervention at asymptomatic period contributes to early recovery

  Passage 1 (n = 1) Passage 2 (n = 8) Passage 3 (n = 23) Passage 4 (n = 46) p values
Laboratory findings
Blood count
 White blood cell count, × 109/L 4.60 6.51 (3.40–7.90) 5.34 (2.30–14.10) 5.21 (2.30–12.80) 0.04
 Neutrophil count, × 109/L 3.40 4.86 (1.60–11.40) 3.61 (1.10–12.20) 3.48 (1.00–7.70) 0.02
 Neutrophil percentage 72.60 74.65 (45.80–91.60) 67.60 (28.40–87.10) 66.79 (34.60–84.50) 0.03
 Lymphocyte count, ×109/L 1.50 0.79 (0.40–1.10) 1.12 (0.50–3.10) 1.59 (0.60–2.90) 0.002
 Lymphocyte percentage 22.00 12.14 (7.10–49.00) 20.97 (8.60–59.20) 30.51 (10.70–53.10) 0.02
 Platelet count, ×109/L 164.00 141.00 (65.00–214.00) 153.50 (57.00–272.00) 172.50 (63.00–311.00) 0.04
 Prothrombin time, s 12.40 14.12 (11.50–16.00) 12.61 (11.40–14.10) 13.27 (11.30–16.90) 0.81
 Red blood cell count(> 5.1 × 1012/L), No. (%) 0 2 (25.00) 2 (8.70) 1 (2.17) 0.04
Blood chemistry
Renal function
 Blood urea nitrogen (< 2.8 mmol/L), No. (%) 0 2 (25.00) 5 (21.74) 4 (8.70) 0.23
 Creatinine (> 123 μmol/L), No. (%) 0 0 1 (4.35) 0 0.30
 Fibrinogen (> 4 g/L), No. (%) 2.64 3.08 (1.94–5.40) 2.75 (1.46–4.57) 2.34 (1.51–4.66) 0.26
 Calcium, (< 2.1 mmol/L), No. (%) 0 2 (25.00) 2 (8.70) 2 (4.35) 0.13
 Magnesium, (< 0.75 mmol/L), No. (%) 0 2 (25.00) 3 (13.04) 7 (15.22) 0.70
 Sodium, (< 135 mmol/L), No. (%) 0 4 (50.00) 6 (26.09) 6 (13.04) 0.04
 Chlorine,(> 108 mmol/L), No. (%) 0 0 1 (4.35) 2 (4.35) 0.83
Liver function
 Alanine aminotransferase (> 40 U/L), No. (%) 0 3 (37.50) 11 (47.83) 14 (30.43) 0.37
 Aspartate aminotransferase, (> 40 U/L), No. (%) 0 3 (37.50) 9 (39.13) 9 (19.57) 0.18
 Total bilirubin (> 28 μmol/L), No. (%) 0 2 (25.00) 1 (4.34) 1 (2.17) 0.03
 Prealbumin levels (< 180 ng/L), No. (%) 0 5 (62.5) 10 (43.48) 9 (19.57) 0.02
 Albumin (< 35 g/L), No. (%) 0 1 (12.50) 0 (0.00) 0 (0.00) 0.01
 Lactate dehydrogenase, (> 245 U/L), No. (%) 1 8 (100) 11 (47.83) 13 (28.26) < 0.001
Infection related biomarker
 Erythrocyte sedimentation rate (> 15 mm/h), No. (%) 0 6 (75.00) 7 (30.43) 11 (23.91) 0.02
 C-reactive protein (> 10 ng/L), No. (%) 1 8 (100.00) 5 (21.74) 7 (15.22) < 0.001
 Procalcitonin (> 0.05 ng/mL), No. (%) 0 0 (0.00) 1 (4.34) 0 (0.00) 0.30
Radiology findings
 Ground glass opacity, No. (%) 1 (100.00) 8 (100.00) 15 (65.22) 16 (34.78) < 0.001
Treatment
 Antiviral 1 (100.00) 8 (100.00) 23 (100.00) 46 (100.00)  
 Antibiotics 1 (100.00) 8 (100.00) 6 (26.09) 9 (19.57) 0.001
 Oxygen inhalation 1 (100.00) 8 (100.00) 16 (69.57) 19 (41.30) 0.002
Severe and critical
 Severed patient, No. (%) 0 (0.00) 4 (50.00) 2 (8.70) 2 (4.35) < 0.001
 Critical patient, No. (%) 0 (0.00) 0 (0.00) 1 (4.35) 0 (0.00) 0.30
 Days in ICU, median, IQR 0 6.5 (3.5–9.5) 5 (3–8) 3 (2–4) 0.22